膀胱内MMC联合阿糖胞苷治疗非肌层浸润性膀胱癌的随机临床试验
该随机临床试验纳入165例非肌层浸润性膀胱癌(NMIBC)患者,比较膀胱内灌注MMC与MMC+阿糖胞苷(Ara-C)的疗效与安全性。结果显示MMC+Ara-C组无复发生存期(RFS)显著更长(P=0.018),中危NMIBC患者差异显著,高危患者不显著;尿pH显著升高,不良事件无显著差异。
要点
- MMC+Ara-C组RFS显著优于MMC组(P=0.018),中危NMIBC获益明显。
- MMC+Ara-C组平均尿pH显著更高(6.56 vs 5.78,P<0.001)。
- 两组不良事件无显著差异(P=0.113),安全性相当。
核心结论
- 膀胱内MMC联合Ara-C对中危NMIBC患者有用且安全。
- Ara-C升高尿pH可能增强抗癌效果。
研究设计与样本
- 随机临床试验,纳入6家医院165例NMIBC患者。
- 随机分为MMC+Ara-C组(81例)和MMC组(87例)。
- MMC+Ara-C方案:30 mg/30 mL + 200 mg/10 mL,每周灌注6周;MMC方案:30 mg/40 mL,同样每周6周。
主要发现
- MMC+Ara-C组总体RFS显著长于MMC组(P=0.018)。
- 中危NMIBC患者中RFS差异显著,高危患者中不显著。
- 平均(SD)尿pH:MMC+Ara-C组6.56(0.61)vs MMC组5.78(0.64),P<0.001。
- 尿pH>7.0的频率:MMC组6.3% vs MMC+Ara-C组26.7%,P<0.001。
- 多因素分析显示尿pH升高与更好结局相关(HR 0.18,95%CI 0.18-0.038;P<0.001)。
关键数值与推荐
- 中危NMIBC患者可考虑MMC+Ara-C膀胱灌注方案。
- 尿pH升高与更好结局相关(HR 0.18,95%CI 0.18-0.038)。
临床怎么用
- 对于中危NMIBC患者,MMC+Ara-C方案可能延长RFS且安全。
- 监测尿pH可能有助于评估疗效,但需进一步验证。
局限性
- 高危NMIBC患者中未观察到显著RFS差异。
- 样本量有限,需更大规模研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the urinary pH, recurrence-free survival (RFS), and safety of adjuvant intravesical therapy in patients with non-muscle-invasive bladder cancer (NMIBC) receiving mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara-C) therapy. PATIENTS AND METHODS: A total of 165 patients with NMIBC from six hospitals were randomly allocated to two groups: weekly instillation of MMC + Ara-C (30 mg/30 mL + 200 mg/10 mL) for 6 weeks and the same instillation schedule of MMC (30 mg/40 mL). The primary outcome was RFS, and secondary outcomes were urinary pH and toxicity in the two groups. RESULTS: A total of 81 and 87 patients were randomised into the MMC and MMC + Ara-C groups, respectively. Overall, the RFS in the MMC + Ara-C group was significantly longer (P = 0.018) than that in the MMC group. A similar significant difference was detected in patients with intermediate-risk NMIBC, but not in those with high-risk NMIBC. The mean (SD) urinary pH was significantly higher in the MMC + Ara-C group than in the MMC group, at 6.56 (0.61) vs 5.78 (0.64) (P < 0.001), and the frequency of a urinary pH of >7.0 in the MMC and MMC + Ara-C groups was 6.3% and 26.7%, respectively (P < 0.001). Multivariate analysis models including clinicopathological features and second transurethral resection demonstrated that increased urinary pH was associated with better outcomes (hazard ratio 0.18, 95% confidential interval 0.18-0.038; P < 0.001). In all, there were 14 and 10 adverse events in the MMC and MMC + Ara-C groups, respectively, without a significant difference (P = 0.113). CONCLUSIONS: Our randomised clinical trial suggested that intravesical therapy with MMC and Ara-C is useful and safe for patients with intermediate-risk NMIBC. Increase in urinary pH with Ara-C is speculated as a mechanism for increased anti-cancer effects.
引用
- Miyata Y, Tsurusaki T, Hayashida Y, et al. Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial. BJU Int. 2021. PMID: 34383381. doi:10.1111/bju.15571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。